Michel: I welcomed the Financial Times Special Report on Combating Malaria. However, I became physically ill after reading Private Sector Role Remains Elusive. We were not contacted by the Financial Times for the story. The article is inaccurate, lacks objectivity, and abuses FT's obligation to be a guardian of the public trust.
I want to set the record straight on the U.S. role “in part of an escalating campaign to undermine programs supporting private sector involvement in the distribution of malaria treatments.” The U.S. Government called for an evidence base for the Affordable Medicines Facility – malaria (AMFm) prior to using U.S. taxpayer funds for its scale up. And we were up front and clear about concerns with an untargeted factory gate subsidy model for reducing prices of Artemisinin based Combination Therapies (ACTs) primarily through the private sector USAID and PMI’s Commitment to Global Efforts to Ensure Prompt Malaria Diagnosis and Treatment.
Mr. Jack mischaracterizes the USG position on subsidies, partnership with the private sector, casts spurious claims on motives and delves into conspiracy theories. The USG supports untargeted subsides when there is no medical downside to overuse and the cost of the treatment is cheap. Deworming kids is the classic example. In our view, a shift towards targeted subsidies approaches make sense given the current malaria epidemiology with decreasing prevalence and concerns of overuse leading to misdiagnosis of other febrile illness and concerns of resistance.
It appears that the concerns were well-founded. In Science, CHAI found that private pharmacies handed out costly malaria drugs indiscriminately to patients with bad fevers without first checking for the parasite. They estimate that more than 400 million doses of malaria drugs went to people without the disease. In some countries, the number of drug doses 'dwarfs the number of actual incident malaria cases that occur.'
Mr. Jack's fails to give voice to USG's commitment to ensuring that interventions targeted for private sector delivery are part of a comprehensive package that includes quality assurance, referrals, supervision, support for supply chain, and other supportive interventions. And he blithely ignores that the U.S. continues to work with partner countries and all parties to apply the lessons learned, support pilot countries, and ensure adherence to WHO guidance on incorporating diagnosis and referral care for patients who may be presenting with other febrile illnesses or severe symptoms.
His citation that “observers suggest US opposition – in turn driving ambivalence towards the AMFm by the World Health Organization, a beneficiary of its support – reflected a reluctance by Washington-based 'Beltway bandits' to lose a share of funding and control' is as reckless and it is baseless. The insinuation is that all global health funders and AMFm working group members are complicit in the ridiculous assertion that AMFM was killed to keep 'Beltway Bandits' flush.
In the article, Mr. Jack denigrates all dedicated public servants and health experts in the U.S. Government and indicts every technical representative in the AMFm working group, for if an anti-private sector case management scheme was at play, all would be party to it -- complicit in silence.
The U.S. is working to ensure key elements of AMFm continue and will allow individual countries to continue to pursue targeted subsidy approaches through the private sector, where there are good reasons to do so, and to design the specifics of how it would work -- these approaches are core to the New Funding Model at the Global Fund and reflect the core principles in the Paris Declaration on Aid Effectiveness.
Chris Thomas
USAID
202 712-1092
chthomas@usaid.gov
On Thu, Apr 25, 2013 at 4:32 AM, SMITALL, Michel wrote:
FT SPECIAL REPORT
Please find attached the Financial Times Special Report on Combating Malaria. This 2013 edition describes progress made to date and expresses fear that an infectious disease claiming 660,000 lives a year is slipping off the agenda. Key issues of the report include the following:
- - Opinion: Malaria goal is daunting
- - Elimination: Falling impact shifts focus to politics
- - Mosquitoes: Protagonists dig deeper in their efforts to crush a complex foe
- - Vaccines: Test setbacks demonstrate formidable nature of the adversary
- - Provision: Private sector role remains elusive
2 attachments
image001.gif
1K
FT_combating_malaria_2013.pdf
5276K
|